News

LibiGel, a testosterone gel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women. LibiGel, when applied once-daily

The partnership between PPD and NHS Research Scotland (NRS) will work to further minimize study start-up times, streamline regulatory approval processes and increase the number of patients recruited

The randomized double-blind placebo-controlled parallel group AssessmenT of Delivery of Drug via A Novel Device to the IntRanasal Cavity for MiGraine PatiEnTs (TARGET) study will include around 200

Catalyst’s intellectual property is a method of treating Tourette Syndrome using GABA aminotransferase inhibitor drugs, including CPP-109 and CPP-115. The method increases presynaptically stored GABA, and enhance GABA

ATS907 is a Rho kinase (ROCK)-selective inhibitor in development as a next-generation eye drop for the reduction of elevated intraocular pressure (IOP) in primary open angle glaucoma and

Mitosol delivers a precise dose of its active ingredient, mitomycin-c, providing ophthalmic surgeons for use in procedures without any change to their current technique. In collaboration with St

As a part of the expanded contract, StayinFront will offer extended hours of technical support across a range of applications for their home office colleagues. StayinFront’s technical staff

The trial data showed that cariprazine treated patients with acute manic episodes experienced significant improvements in symptoms compared to placebo-treated patients. The results of this study were consistent

The novel anti-cancer molecule is expected to go into clinical trials by 2012 and both the companies will continue the collaboration in the development phase as well. Endo